MX9204077A - SHORT-TERM ANTI-CD3 STIMULATION OF LYMPHOCYTES TO INCREASE THEIR ACTIVITY IN VIVO. - Google Patents

SHORT-TERM ANTI-CD3 STIMULATION OF LYMPHOCYTES TO INCREASE THEIR ACTIVITY IN VIVO.

Info

Publication number
MX9204077A
MX9204077A MX9204077A MX9204077A MX9204077A MX 9204077 A MX9204077 A MX 9204077A MX 9204077 A MX9204077 A MX 9204077A MX 9204077 A MX9204077 A MX 9204077A MX 9204077 A MX9204077 A MX 9204077A
Authority
MX
Mexico
Prior art keywords
lymphocytes
vivo
stimulation
activity
short
Prior art date
Application number
MX9204077A
Other languages
Spanish (es)
Inventor
Dan L Longo
Augusto C Ochoa
Cynthia Loeffler
Walter Urea
Original Assignee
Dan L Longo
Augusto C Ochoa
Cynthia Loeffler
Walter Urea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dan L Longo, Augusto C Ochoa, Cynthia Loeffler, Walter Urea filed Critical Dan L Longo
Publication of MX9204077A publication Critical patent/MX9204077A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está dirigida a un método para incrementar la respuesta inmulógica in vivo de linfocitos mediante la estimulación de los linfocitos in vitro en presencia de un anticuerpo monoclonal anti-CD3 por menos de alrededor de 24 horas para formar linfocitos estimulados; infundir los linfocitos estimulados en un mamíferos portador de un tumor; y administrar IL-2 al mamífero. Como resultado de este método, los linfocitos estimulados anti-CD3 exhiben una mejorada producción inmunoterapéutica, por ejemplo citotoxicidad o de linfoquina in vivo, como se representa por una reducción en el número de tumores de al menos alrededor de 20.The present invention is directed to a method of increasing the in vivo immune response of lymphocytes by stimulating lymphocytes in vitro in the presence of an anti-CD3 monoclonal antibody for less than about 24 hours to form stimulated lymphocytes; infuse stimulated lymphocytes into a tumor-bearing mammal; and administer IL-2 to the mammal. As a result of this method, anti-CD3 stimulated lymphocytes exhibit improved immunotherapeutic production, for example cytotoxicity or lymphokine in vivo, as represented by a reduction in the number of tumors of at least about 20.

MX9204077A 1991-07-10 1992-07-10 SHORT-TERM ANTI-CD3 STIMULATION OF LYMPHOCYTES TO INCREASE THEIR ACTIVITY IN VIVO. MX9204077A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72810791A 1991-07-10 1991-07-10

Publications (1)

Publication Number Publication Date
MX9204077A true MX9204077A (en) 1994-06-30

Family

ID=24925447

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9204077A MX9204077A (en) 1991-07-10 1992-07-10 SHORT-TERM ANTI-CD3 STIMULATION OF LYMPHOCYTES TO INCREASE THEIR ACTIVITY IN VIVO.

Country Status (12)

Country Link
US (1) US5316763A (en)
EP (1) EP0593625B1 (en)
JP (1) JP3507489B2 (en)
AT (1) ATE142885T1 (en)
AU (1) AU674128B2 (en)
CA (1) CA2111564A1 (en)
DE (1) DE69213943T2 (en)
IE (1) IE922233A1 (en)
IL (1) IL102460A (en)
MX (1) MX9204077A (en)
WO (1) WO1993000918A1 (en)
ZA (1) ZA925155B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
WO1990004412A1 (en) * 1988-10-27 1990-05-03 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
AU1524095A (en) * 1994-01-27 1995-08-15 Cellcor, Inc. Ex vivo activation of immune cells
AU2604895A (en) * 1994-05-31 1995-12-21 Dan L. Longo Short-term anti-cd3 stimulation of lymphocytes to increase their (in vivo) activity
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US5723503A (en) * 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
AU6104396A (en) * 1995-06-07 1996-12-30 Imclone Systems Incorporated Therapeutic uses of monoclonal antibody ta99 in combination with interleukin-2 and/or lymphokine activated killer cells
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO1998014206A1 (en) * 1996-10-04 1998-04-09 Thomas Jefferson University T cells mediating an immune response and methods of use
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
FR2821947B1 (en) * 2001-03-12 2003-05-16 Canon Kk METHOD AND DEVICE FOR VALIDATING IMAGE DEFINING PARAMETERS
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
JP6074916B2 (en) * 2012-05-22 2017-02-08 東洋製罐グループホールディングス株式会社 Cell activation method and cell culture method
CN107502589A (en) * 2017-08-04 2017-12-22 北京世纪劲得生物技术有限公司 A kind of tumor infiltrating lymphocyte and mononuclearcell co-culture method

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049611B2 (en) * 1980-10-02 1993-12-08 Hooper Trading Co. N.V. A T-cell growth factor, and a process of producing the same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8405555D0 (en) * 1984-03-02 1984-04-04 Rees A D M Macrophage activating factors
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
EP0203403B1 (en) * 1985-05-01 1992-10-28 Asahi Kasei Kogyo Kabushiki Kaisha A cloned t cell capable of recognizing tumors and a t cell antigen receptor
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
AU7873187A (en) * 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
US4882424A (en) * 1987-05-11 1989-11-21 Dana-Farber Cancer Institute, Inc. Activation antigen
WO1989005657A1 (en) * 1987-12-17 1989-06-29 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
FI105320B (en) * 1988-04-04 2000-07-31 Oncogen Procedure for Preparation of Antibody Heteroconjugates for Use in Regulating Lymphocyte Activity and Diagnosis
JPH03503844A (en) * 1988-04-15 1991-08-29 リサーチ　コーポレーシヨン　テクノロジーズ　インコーポレーテツド LAK cell cytotoxin
AU4485089A (en) * 1988-10-21 1990-05-14 Brigham And Women's Hospital Activation and growth of human tumor-infiltrating lymphocytes using antibodies to cd3 or tcr
WO1990004412A1 (en) * 1988-10-27 1990-05-03 Regents Of The University Of Minnesota Liposome immunoadjuvants containing il-2
GR1001034B (en) * 1989-07-21 1993-03-31 Ortho Pharma Corp Method for stimulating proliferation of peripheral blood lymphocytes.
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer

Also Published As

Publication number Publication date
EP0593625A4 (en) 1994-11-02
DE69213943T2 (en) 1997-04-10
ZA925155B (en) 1993-04-28
AU674128B2 (en) 1996-12-12
EP0593625B1 (en) 1996-09-18
AU2300592A (en) 1993-02-11
IL102460A (en) 2001-08-26
US5316763A (en) 1994-05-31
IE922233A1 (en) 1993-01-13
JPH07502486A (en) 1995-03-16
WO1993000918A1 (en) 1993-01-21
IL102460A0 (en) 1993-01-14
DE69213943D1 (en) 1996-10-24
JP3507489B2 (en) 2004-03-15
EP0593625A1 (en) 1994-04-27
CA2111564A1 (en) 1993-01-21
ATE142885T1 (en) 1996-10-15

Similar Documents

Publication Publication Date Title
MX9204077A (en) SHORT-TERM ANTI-CD3 STIMULATION OF LYMPHOCYTES TO INCREASE THEIR ACTIVITY IN VIVO.
Xu et al. Regulation of antitumor immune responses by the IL‐12 family cytokines, IL‐12, IL‐23, and IL‐27
Boyman et al. Modulation of T cell responses by IL-2 and IL-2 complexes
ATE246513T1 (en) PREPARATIONS AND METHODS FOR THE TREATMENT OF CANCER AND HYPERPROLIFERING DISEASES
JP7268039B2 (en) Methods of producing natural killer cells and compositions for cancer therapy
RU94034104A (en) Method of increase of chemotherapeutic agent cytotoxicity, set for treatment and agent for drug production
DE69433590D1 (en) CELLULAR VACCINE AND THEIR USE FOR TREATING MALIGNAS, SOLID TUMORS
DK0668781T3 (en) Lymphocyte therapy of cancer in combination with tumor antigens
NZ182891A (en) Vaccine for stimulating the immune mechanism of mammals to species-specific tumours
ATE71662T1 (en) PHARMACEUTICAL PREPARATION CONTAINING A HUMAN GRANULOCYTE COLONIZATION FACTOR FOR THE TREATMENT OF LEUKOPAENIA.
RU93042874A (en) POLYPEPTIDE NATURE COMPOUNDS, METHOD FOR THEIR PRODUCTION, A COMPOSITION ON THEIR BASIS, THEIR APPLICATION IN ANTI-CANCER THERAPY
ES458197A1 (en) Immuniological adjuvant peptidoglycans compounds and methods of preparation thereof
HU9301677D0 (en) Polypeptide-type compounds of medical effect
Eguchi et al. Interferon-α and interleukin-12 gene therapy of cancer: interferon-α induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing
NZ224116A (en) Compositions of interleukin-2 and fk565; method of stimulation of the immune system and package
ES2039236T3 (en) METHOD FOR PREPARING A THERAPEUTIC COMPOSITION OF INTERLENQUINE-2 AND / OR INTERFERON-BETA AND TUMOR NECROSIS FACTOR.
Metwali et al. IL-2 contributes to the IL-5 response in granulomas from mice infected with Schistosoma mansoni.
ES8800981A1 (en) Process and composition for treatment of cancer and non-malignant tumors.
Nakano et al. Augmentation of the generation of cytotoxic T lymphocytes against syngeneic tumor cells by recombinant human tumor necrosis factor
DE69433110D1 (en) ALLOGENIC VACCINE AND SYNTHESIS METHOD FOR THE SAME
DE19721211A1 (en) Three-fold treatment of tumours providing synergistic effect
Flemming et al. SARCOMA CELLS ENGINEERED TO SECRETE IFN-γ OR IL-2 ACQUIRE SENSITIZATION TO IMMUNE CELL KILLING VIA DIFFERENT MECHANISMS
Trinchieri Interleukin-12: Clinical Potential in Infectious Diseases, AIDS and Cancer
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2
DE4411425A1 (en) Prepn. of tumour vaccine for active specific immuno-therapy

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees